Navigation Links
MAP Pharmaceuticals Appoints Scott R. Ward as Chairman of the Board of Directors
Date:2/18/2011

MOUNTAIN VIEW, Calif., Feb. 18, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the appointment of Scott R. Ward as Chairman of its Board of Directors. Steven A. Elms, the incumbent Chairman and an original venture capital investor in the Company, will step down from the Board of Directors after over six years of service.

"I want to thank Steve for all his contributions to the Company and the Board as we have grown from an early concept to a late-stage development organization.  I look forward to working with Scott as we prepare for our first NDA submission and potential product launch," said Timothy S. Nelson, MAP Pharmaceuticals' President and Chief Executive Officer.  "Scott brings 30 years of industry and commercial experience and his leadership will be greatly valued as the Company continues to grow."

"I am pleased to take on the role of Chairman of the MAP Pharmaceuticals Board at this time, as the Company is transitioning into a commercial organization," said Scott R. Ward. "With the recently announced Allergan collaboration, the Company has established a strategic pathway for the potential commercialization of LEVADEX for the acute treatment of migraine."

Mr. Ward has extensive experience in the healthcare industry including 15 years as an operating business leader, and various roles in regulatory affairs, clinical research and business development since he joined Medtronic, Inc. in 1981. Mr. Ward has led the development and commercial launch of 20 significant new products and therapies in the cardiovascular and neurological markets.  

Most recently, Mr. Ward was Senior Vice President and President of the CardioVascular business of Medtronic which generated approximately $3 billion in annual sales.  He was responsible for all worldwide operations of the CardioVascular sector including the Coronary, Peripheral, Endovascular and Structural Heart Disease businesses.  Previously, Mr. Ward served as Senior Vice President and President of Medtronic Neurological and Diabetes, and Vice President and General Manager of the Medtronic Drug Delivery Business.  Mr. Ward has served as a Director of MAP Pharmaceuticals since 2008.

About MAP Pharmaceuticals MAP Pharmaceuticals is an emerging biopharmaceutical Company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX™ orally inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of its Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Forward-Looking StatementsIn addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' LEVADEX product candidate. Actual results may differ materially from current expectations based on risks and uncertainties affecting the Company's business, including, without limitation, risks and uncertainties relating to the preparation and filing of a New Drug Application, the regulatory process to have the Company's LEVADEX product candidate approved for commercial use and the potential benefits from the collaboration between MAP Pharmaceuticals and Allergan. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2010, available at http://edgar.sec.gov. Contact:Lisa Borland650-386-3122lborland@mappharma.com
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Conatus Pharmaceuticals Initiates Confirmatory Phase 2 Clinical Trial of CTS-1027 for the Treatment of Hepatitis C Virus (HCV)
2. Dr. Abraham Abuchowski of Prolong Pharmaceuticals Honored With Inaugural Tibbetts Award by the U.S. Small Business Administration
3. AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
4. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2010 Results Conference Call on Friday, February 25, 2011
5. Cumberland Pharmaceuticals to Announce 2010 Financial Results on March 8, 2011
6. Valeant Pharmaceuticals to Present at RBC Capital Markets 2011 Healthcare Conference
7. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results Teleconference and Webcast
8. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPARELâ„¢ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
9. ADVENTRX Pharmaceuticals Provides Update on ANX-514
10. Valeant Pharmaceuticals to Announce 2010 Fourth Quarter and Full Year Results on February 24, 2011
11. Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
Breaking Medicine News(10 mins):